SCYNEXIS Inc. Common Stock (SCYX)

About SCYX

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fu…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

18

Website

www.scynexis.com/

Fundamentals

1-day range

$5.35$5.67

Market cap

$50.35M

P/E (trailing)

—

P/E (forward)

-2.33

EPS (trailing)

$-2.92

Dividend yield

—

Beta

1.07

Avg. volume

141.2K

Dividend pay date

July 17, 2020

Forecasts

3 analyst ratings

SCYNEXIS Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SCYX

  SCYNEXIS Inc. Common Stock

  $5.44

  ▼ 1.45%
  Market cap $50.35MP/E —
  $3.53$10.48
• MREO

  Mereo BioPharma Group plc American Depositary Shares

  $0.2545

  ▼ 6.43%
  Market cap $48.95MP/E —
  $0.2$2.37
• IBO

  Impact BioMedical Inc. Common Stock

  $0.444

  ▲ 0.68%
  Market cap $48.61MP/E 0.52
  $0.37$0.83
• RNXT

  RenovoRx Inc. Common Stock

  $1.68

  ▲ 13.18%
  Market cap $47.81MP/E —
  $0.7006$1.56
• TCRT

  Alaunos Therapeutics Inc. Common Stock

  $1.56

  ▼ 6.02%
  Market cap $46.52MP/E —
  $1.62$4.59
• RADX

  Radiopharm Theranostics Limited American Depositary Shares

  $2.41

  ▲ 6.64%
  Market cap $44.71MP/E —
  $0.009$0.04
• IMMP

  Immutep Limited American Depositary Shares

  $0.3848

  ▲ 1.26%
  Market cap $55.99MP/E —
  $0.028$0.47

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $33
  benzinga · 8/13/2026